RxDoctor Payments Data

Richard Wynn, MD

Family Medicine · Charlotte, NCNPI 1356365480

Payments from drug & device makers

$13,158in general payments, 2019–2025

Across 785 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • AstraZeneca$945
  • AbbVie$793
  • Astellas Pharma US Inc$756
  • Pfizer$737
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,83798%
  • Education$3222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company96$1,550
Gilead82$1,240
AstraZeneca(2 entities)57$945
AbbVie(2 entities)58$793
Astellas Pharma US Inc35$756
Pfizer48$737
Amgen(2 entities)41$721
Johnson & Johnson(2 entities)36$549
Lilly USA, LLC29$427
GSK23$389
Novo Nordisk24$353
Novartis21$312
Boehringer Ingelheim16$305
Biohaven Pharmaceuticals, Inc.18$286
Otsuka America Pharmaceutical, Inc.15$283
Biohaven Pharmaceutical Holding Company Ltd.15$279
Abbott12$273
Takeda Pharmaceuticals U.S.A., Inc.15$263
Merck12$247
Amarin Pharma, Inc.13$205
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$196
Indivior Inc.9$171
Sumitomo Pharma America, Inc.7$168
Bayer8$125
Antares Pharma, Inc.5$111
Janssen Products, LP1$89
Theratechnologies Inc.4$87
Exact Sciences3$78
Clarus Therapeutics Inc.3$64
Orexo US, Inc.4$62
E.r. Squibb & Sons, L.L.C.3$58
Corcept Therapeutics3$58
Idorsia Pharmaceuticals US Inc3$56
Daiichi Sankyo Inc.3$56
Teva Pharmaceuticals USA, Inc.4$55
Vanda Pharmaceuticals Inc.2$47
Halozyme Inc2$41
VBI Vaccine (delaware) Inc.3$41
Axsome Therapeutics, Inc.2$36
Insightec,inc1$33
Cepheid1$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$31
Organogenesis Inc.1$30
Assertio Therapeutics, Inc.2$30
Medtronic(2 entities)2$28
Jazz Pharmaceuticals Inc.2$27
Kowa Pharmaceuticals America, Inc.2$27
Nevro Corp.1$26
Napo Pharmaceuticals Inc2$25
IBSA Pharma Inc.1$22
Corium, LLC1$22
ARS Pharmaceuticals Operations, Inc.1$21
Invivyd Inc1$20
Cranial Technologies, Inc1$19
Organon1$19
Zimmer Biomet1$19
Phathom Pharmaceuticals, Inc.1$18
Forte Bio-pharma LLC1$17
Grifols USA, LLC1$16
Shire North American Group Inc1$16

How this compares

$13,158 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$109,934
Medicare patients
395
Services billed
1,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala71$290,945
OzempicSemaglutide107$150,322
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf24$112,016
MounjaroTirzepatide83$105,453
LinzessLinaclotide104$84,510
EliquisApixaban96$80,219
Invokamet XrCanagliflozin/Metformin Hcl75$75,422
TrulicityDulaglutide46$74,984
JulucaDolutegravir/Rilpivirine19$73,293
OtezlaApremilast13$62,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$59,698
TrintellixVortioxetine Hydrobromide91$54,400
FarxigaDapagliflozin Propanediol64$53,742
JardianceEmpagliflozin43$52,543
Xigduo XrDapaglifloz Propaned/Metformin58$51,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,240$367,90096 claims
Lilly USA, LLCMounjaro, Trulicity, Forteo$427$227,322140 claims
Novo NordiskOzempic, Rybelsus$353$187,483135 claims
PfizerEliquis, Nurtec Odt$737$118,696130 claims
Janssen Products, LPSymtuza$89$112,01624 claims
AbbVieLinzess, Vraylar, Restasis$793$111,360132 claims
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat$305$103,762100 claims
Viiv Healthcare CompanyJuluca$1,550$73,29319 claims
AstraZenecaFarxiga, Breztri Aerosphere$945$71,72981 claims
MerckJanuvia, Janumet Xr$247$69,53964 claims
GSKTrelegy Ellipta, Shingrix$389$68,688106 claims
AmgenOtezla$721$62,64413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →